MP88
2021-08-04
Vaccine vaccine
Why Shares of Moderna Are Up Today<blockquote>为什么 Moderna 股价今天上涨</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":807248031,"tweetId":"807248031","gmtCreate":1628040781123,"gmtModify":1633754141323,"author":{"id":3582798202671514,"idStr":"3582798202671514","authorId":3582798202671514,"authorIdStr":"3582798202671514","name":"MP88","avatar":"https://static.tigerbbs.com/98ab4cdb5a6f628d50eef8b5db5303aa","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Vaccine vaccine</p></body></html>","htmlText":"<html><head></head><body><p>Vaccine vaccine</p></body></html>","text":"Vaccine vaccine","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/807248031","repostId":1199496640,"repostType":4,"repost":{"id":"1199496640","kind":"news","pubTimestamp":1628039112,"share":"https://www.laohunote.com/m/news/1199496640?lang=zh_CN&edition=full","pubTime":"2021-08-04 09:05","market":"us","language":"en","title":"Why Shares of Moderna Are Up Today<blockquote>为什么 Moderna 股价今天上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199496640","media":"The Motley Fool","summary":"A regulatory action is giving investors a glimpse of its business beyond the pandemic.\nWhat happened","content":"<p><i>A regulatory action is giving investors a glimpse of its business beyond the pandemic.</i></p><p><blockquote><i>监管行动让投资者得以一窥其在疫情之外的业务。</i></blockquote></p><p> <h3><b>What happened</b></h3> Shares of <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> are up 9% as of 2:45 p.m. EDT today, after the Food and Drug Administration (FDA) granted Fast Track designation for mRNA-1345, the company's vaccine candidate for respiratory syncytial virus (RSV). In April, the company provided data showing an 11-fold and 20-fold increase in neutralizing antibodies for RSV-B and RSV-A, respectively, compared with its previous vaccine candidate.</p><p><blockquote><h3><b>发生了什么事</b></h3>股份<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>截至美国东部时间今天下午 2:45，上涨 9%，此前美国食品和药物管理局 (FDA) 授予该公司针对呼吸道合胞病毒 (RSV) 的候选疫苗 mRNA-1345 的快速通道指定。4 月份，该公司提供的数据显示，与之前的候选疫苗相比，RSV-B 和 RSV-A 的中和抗体分别增加了 11 倍和 20 倍。</blockquote></p><p> <h3><b>So what</b></h3> RSV typically produces cold-like symptoms that last for a week or two. However, it does lead to about 58,000 hospitalizations in young children and 177,000 in older adults every year in the U.S. The agency's designation only applies to people over 60 years old.</p><p><blockquote><h3><b>那又怎样</b></h3>RSV通常会产生持续一两周的感冒样症状。然而，在美国，它确实导致每年约有 58,000 名幼儿和 177,000 名老年人住院。该机构的指定仅适用于 60 岁以上的人。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8a6a5fe1572f41187b8240e772c0216\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> There is currently no approved vaccine for RSV. The Fast Track designation is a way for the FDA to expedite development of drugs that treat a currently unmet need. The process has lost some of its meaning in recent years. As an example, 73% of new drugs received the designation in 2018.</p><p><blockquote>目前没有批准的RSV疫苗。快速通道指定是 FDA 加快开发治疗当前未满足需求的药物的一种方式。近年来，这一过程已经失去了一些意义。例如，2018年有73%的新药获得了认定。</blockquote></p><p> <h3><b>Now what</b></h3> If Moderna can commercialize the drug, it won't have to share the rewards. It owns 100% of the asset. Although the market is estimated at less than $1 billion, the impact could be more substantial. It plans to create a seasonal respiratory vaccine to protect against RSV, COVID-19, and influenza. Insurers would be more likely to push that drug, as combining one shot for multiple protections is likely to increase compliance with recommended inoculations.</p><p><blockquote><h3><b>现在呢</b></h3>如果 Moderna 能够将该药物商业化，它就不必分享回报。它拥有100%的资产。尽管市场估计不到10亿美元，但影响可能更大。它计划研发一种季节性呼吸道疫苗，以预防呼吸道合胞病毒、新冠肺炎病毒和流感。保险公司更有可能推广这种药物，因为将一针疫苗结合起来进行多种保护可能会提高对推荐接种的依从性。</blockquote></p><p> In the short term, the $19.2 billion Moderna expects from its COVID-19 vaccine far outweighs any impact from the RSV vaccine. However, it's a positive signal that the company will be able to leverage its mRNA platform andcommercialize drugsbeyond the pandemic.</p><p><blockquote>短期内，Moderna 预计其 COVID-19 疫苗将带来 192 亿美元的收入远远超过 RSV 疫苗的任何影响。然而，这是一个积极的信号，表明该公司将能够利用其 mRNA 平台并将药物商业化到疫情以外。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Shares of Moderna Are Up Today<blockquote>为什么 Moderna 股价今天上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Shares of Moderna Are Up Today<blockquote>为什么 Moderna 股价今天上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 09:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i>A regulatory action is giving investors a glimpse of its business beyond the pandemic.</i></p><p><blockquote><i>监管行动让投资者得以一窥其在疫情之外的业务。</i></blockquote></p><p> <h3><b>What happened</b></h3> Shares of <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> are up 9% as of 2:45 p.m. EDT today, after the Food and Drug Administration (FDA) granted Fast Track designation for mRNA-1345, the company's vaccine candidate for respiratory syncytial virus (RSV). In April, the company provided data showing an 11-fold and 20-fold increase in neutralizing antibodies for RSV-B and RSV-A, respectively, compared with its previous vaccine candidate.</p><p><blockquote><h3><b>发生了什么事</b></h3>股份<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>截至美国东部时间今天下午 2:45，上涨 9%，此前美国食品和药物管理局 (FDA) 授予该公司针对呼吸道合胞病毒 (RSV) 的候选疫苗 mRNA-1345 的快速通道指定。4 月份，该公司提供的数据显示，与之前的候选疫苗相比，RSV-B 和 RSV-A 的中和抗体分别增加了 11 倍和 20 倍。</blockquote></p><p> <h3><b>So what</b></h3> RSV typically produces cold-like symptoms that last for a week or two. However, it does lead to about 58,000 hospitalizations in young children and 177,000 in older adults every year in the U.S. The agency's designation only applies to people over 60 years old.</p><p><blockquote><h3><b>那又怎样</b></h3>RSV通常会产生持续一两周的感冒样症状。然而，在美国，它确实导致每年约有 58,000 名幼儿和 177,000 名老年人住院。该机构的指定仅适用于 60 岁以上的人。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8a6a5fe1572f41187b8240e772c0216\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> There is currently no approved vaccine for RSV. The Fast Track designation is a way for the FDA to expedite development of drugs that treat a currently unmet need. The process has lost some of its meaning in recent years. As an example, 73% of new drugs received the designation in 2018.</p><p><blockquote>目前没有批准的RSV疫苗。快速通道指定是 FDA 加快开发治疗当前未满足需求的药物的一种方式。近年来，这一过程已经失去了一些意义。例如，2018年有73%的新药获得了认定。</blockquote></p><p> <h3><b>Now what</b></h3> If Moderna can commercialize the drug, it won't have to share the rewards. It owns 100% of the asset. Although the market is estimated at less than $1 billion, the impact could be more substantial. It plans to create a seasonal respiratory vaccine to protect against RSV, COVID-19, and influenza. Insurers would be more likely to push that drug, as combining one shot for multiple protections is likely to increase compliance with recommended inoculations.</p><p><blockquote><h3><b>现在呢</b></h3>如果 Moderna 能够将该药物商业化，它就不必分享回报。它拥有100%的资产。尽管市场估计不到10亿美元，但影响可能更大。它计划研发一种季节性呼吸道疫苗，以预防呼吸道合胞病毒、新冠肺炎病毒和流感。保险公司更有可能推广这种药物，因为将一针疫苗结合起来进行多种保护可能会提高对推荐接种的依从性。</blockquote></p><p> In the short term, the $19.2 billion Moderna expects from its COVID-19 vaccine far outweighs any impact from the RSV vaccine. However, it's a positive signal that the company will be able to leverage its mRNA platform andcommercialize drugsbeyond the pandemic.</p><p><blockquote>短期内，Moderna 预计其 COVID-19 疫苗将带来 192 亿美元的收入远远超过 RSV 疫苗的任何影响。然而，这是一个积极的信号，表明该公司将能够利用其 mRNA 平台并将药物商业化到疫情以外。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/why-shares-of-moderna-are-up-today/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/03/why-shares-of-moderna-are-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199496640","content_text":"A regulatory action is giving investors a glimpse of its business beyond the pandemic.\nWhat happened\nShares of Moderna, Inc. are up 9% as of 2:45 p.m. EDT today, after the Food and Drug Administration (FDA) granted Fast Track designation for mRNA-1345, the company's vaccine candidate for respiratory syncytial virus (RSV). In April, the company provided data showing an 11-fold and 20-fold increase in neutralizing antibodies for RSV-B and RSV-A, respectively, compared with its previous vaccine candidate.\nSo what\nRSV typically produces cold-like symptoms that last for a week or two. However, it does lead to about 58,000 hospitalizations in young children and 177,000 in older adults every year in the U.S. The agency's designation only applies to people over 60 years old.\nIMAGE SOURCE: GETTY IMAGES.\nThere is currently no approved vaccine for RSV. The Fast Track designation is a way for the FDA to expedite development of drugs that treat a currently unmet need. The process has lost some of its meaning in recent years. As an example, 73% of new drugs received the designation in 2018.\nNow what\nIf Moderna can commercialize the drug, it won't have to share the rewards. It owns 100% of the asset. Although the market is estimated at less than $1 billion, the impact could be more substantial. It plans to create a seasonal respiratory vaccine to protect against RSV, COVID-19, and influenza. Insurers would be more likely to push that drug, as combining one shot for multiple protections is likely to increase compliance with recommended inoculations.\nIn the short term, the $19.2 billion Moderna expects from its COVID-19 vaccine far outweighs any impact from the RSV vaccine. However, it's a positive signal that the company will be able to leverage its mRNA platform andcommercialize drugsbeyond the pandemic.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2553,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/807248031"}
精彩评论